1. Sherr CJ. Cancer cell cycles. Science. 1996; 274:1672–1677. PMID:
8939849.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3:415–428. PMID:
12042769.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004; 22:4632–4642. PMID:
15542813.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985; 313:144–147. PMID:
2981413.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Liu Y, Pang JC, Dong S, Mao B, Poon WS, Ng HK. Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol. 2005; 36:416–425. PMID:
15892004.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Laffaire J, Everhard S, Idbaih A, et al. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol. 2011; 13:84–98. PMID:
20926426.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Hegi ME, zur Hausen A, Rüedi D, Malin G, Kleihues P. Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. Int J Cancer. 1997; 73:57–63. PMID:
9334810.
8. Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene. 1991; 6:1313–1318. PMID:
1886708.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Zhang L, Wang M, Wang W, Mo J. Incidence and prognostic value of multiple gene promoter methylations in gliomas. J Neurooncol. 2014; 116:349–356. PMID:
24197988.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM. Predicting aberrant CpG island methylation. Proc Natl Acad Sci U S A. 2003; 100:12253–12258. PMID:
14519846.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Shen L, Kondo Y, Guo Y, et al. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet. 2007; 3:2023–2036. PMID:
17967063.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res. 2003; 9:2673–2677. PMID:
12855646.
13. Zare M, Jazii FR, Alivand MR, Nasseri NK, Malekzadeh R, Yazdanbod M. Qualitative analysis of Adenomatous Polyposis Coli promoter: hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker. BMC Cancer. 2009; 9:24. PMID:
19149902.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 1994; 22:2990–2997. PMID:
8065911.
15. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93:9821–9826. PMID:
8790415.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Goldmit M, Bergman Y. Monoallelic gene expression: a repertoire of recurrent themes. Immunol Rev. 2004; 200:197–214. PMID:
15242406.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Kloosterhof NK, de Rooi JJ, Kros M, et al. Molecular subtypes of glioma identified by genome-wide methylation profiling. Genes Chromosomes Cancer. 2013; 52:665–674. PMID:
23629961.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Bird AP. CpG-rich islands and the function of DNA methylation. Nature. 1986; 321:209–213. PMID:
2423876.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A. 2002; 99:3740–3745. PMID:
11891299.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Gama-Sosa MA, Slagel VA, Trewyn RW, et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 1983; 11:6883–6894. PMID:
6314264.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Esteller M. Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer. 2000; 36:2294–2300. PMID:
11094302.
22. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999; 21:163–167. PMID:
9988266.
23. Cecener G, Tunca B, Egeli U, et al. The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma. Cell Mol Neurobiol. 2012; 32:237–244. PMID:
21928112.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Lorente A, Mueller W, Urdangarín E, et al. RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol. 2009; 19:279–292. PMID:
18616639.
25. Yu J, Zhang H, Gu J, et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer. 2004; 4:65. PMID:
15367334.
![crossref](/image/icon/bnr_ref_cross.gif)